Alirocumab's ODYSSEY continues into once-monthly dosing territory
This article was originally published in Scrip
Sanofi and Regeneron have announced positive top-line Phase III data for their investigational PCSK9 inhibitor alirocumab when dosed every four weeks, narrowing what little gap there was between it and its main rival Amgen's evolocumab.
You may also be interested in...
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.